Semantic Rehabilitation for Patients With Primary Progressive Semantic

Status Recruiting

Clinical Trial Summary

This project aims to measure the effect of a semantic rehabilitation protocol for patients with primary progressive semantic aphasia and using the SCED methodology.

Clinical Trial Description

The damage on the semantic system is at the heart of the clinical picture of semantic primary progressive aphasia (PPA), a neuro-evolutionary pathology. In other words, patients gradually lose access to concepts, general knowledge, word memory and meaning. In the absence of effective pharmacological treatment to reduce the symptoms evoked by patients and improve their quality of life, the arguments in favour of speech and language therapy are multiplying. Numerous lexico-semantic multimodal indication therapies have been described in scientific studies. The most studied is semantic rehabilitation through the analysis of semantic features, which has shown its effectiveness in the context of vascular and post-traumatic aphasia. However, there are only few studies and applications in neuro-evolutionary pathologies such as semantic PPA and those studies are complicated by methodological biases. It has been shown that relearned knowledge is more likely to be retained and transferred to everyday life (generalisation) if the material used is specific to the needs of each individual. Given the heterogeneity of clinical profiles in neuro-evolving pathologies and the inter-individual variability, the personalised approach should be favoured. To evaluate the effect of semantic therapy in patients with semantic PPA, this study therefore proposes to use the SCED (Single Case Experimental Design) methodology. In addition to allowing an individual analysis, this methodology has the advantage of corresponding to a high level of evidence due to the acquisition of repeated measures and the randomisation of the introduction of the treatment. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04957537
Study type	Interventional
Source	University Hospital, Toulouse
Contact	Jérémie PARIENTE, MD PhD
Phone	0561777686
Email	pariente.j@chu-toulouse.fr
Status	Recruiting
Phase	N/A
Start date	September 20, 2021
Completion date	September 2025

View Details

See also
Status	Clinical Trial	Phase
Suspended	`NCT04290988` - Circuitry Assessment and Reinforcement Training Effects on Recovery	N/A
Completed	`NCT04045990` - Network Modulation in Alzheimer's Disease	N/A
Recruiting	`NCT05443633` - Enhancing Language Function in Aphasia	N/A
Completed	`NCT05860647` - Transmagnetic Stimulation Pilot in Primary Progressive Aphasia	N/A
Recruiting	`NCT03887481` - Targeting Language-specific and Executive-control Networks With Transcranial Direct Current Stimulation in Logopenic Variant PPA	N/A
Completed	`NCT03728582` - Rehabilitating and Decelerating Language Loss in Primary Progressive Aphasia With tDCS Plus Language Therapy	N/A
Completed	`NCT01465360` - Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center	N/A
Completed	`NCT02541097` - Preventing Language Decline in Dementia	N/A
Recruiting	`NCT00537004` - Language in Primary Progressive Aphasia
Recruiting	`NCT05741853` - Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia	N/A
Active, not recruiting	`NCT05742698` - Nabilone for Agitation in Frontotemporal Dementia	Phase 2
Completed	`NCT02439853` - Communication Bridge Speech Therapy Research Study	N/A
Completed	`NCT01623284` - PiB PET Scanning in Speech and Language Based Dementias	Phase 1
Completed	`NCT04726527` - Clinical Evaluation of Florbetapir in Primary Progressive Aphasia
Completed	`NCT03076671` - More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease	N/A
Completed	`NCT05537688` - Identification of Graphic Markers of Neurocognitive Disorders (MG)
Completed	`NCT05525377` - Better Living With Non-memory-led Dementia	N/A
Completed	`NCT02928848` - Transcranial Direct Current Stimulation for Primary Progressive Aphasia	N/A
Completed	`NCT04939818` - Clinical Feasibility of Speech Phenotyping for Remote Assessment of Neurodegenerative and Psychiatric Disorders
Enrolling by invitation	`NCT05368350` - Treating Primary Progressive Aphasia and Apraxia of Speech Using Non-invasive Brain Stimulation	Early Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Semantic Rehabilitation for Patients With Primary Progressive Semantic Aphasia — SCED-APPvs

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms